DexCom Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 7,600

Employees

  • Stock Symbol
  • DXCM

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $116.18
  • (As of Wednesday Closing)

DexCom General Information

Description

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Contact Information

Website
www.dexcom.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Monitoring Equipment
Other Industries
Other Healthcare Technology Systems
Other Devices and Supplies
Stock Exchange
NAS
Primary Office
  • 6340 Sequence Drive
  • San Diego, CA 92121
  • United States
+1 (855) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DexCom Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$116.18 $112.20 $74.75 - $139.55 $44.3B 382M 5.11M $0.98

DexCom Financials Summary

In Thousands,
USD 		TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 35,923,839 43,500,170 51,227,886 34,718,025
Revenue 3,403,000 2,909,800 2,448,500 1,926,700
EBITDA 696,500 581,700 395,600 370,000
Net Income 377,000 341,200 216,900 493,600
Total Assets 6,596,200 5,391,700 4,933,300 4,290,500
Total Debt 2,718,900 2,145,000 2,157,900 1,839,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DexCom Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DexCom‘s full profile, request access.

Request a free trial

DexCom Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore DexCom‘s full profile, request access.

Request a free trial

DexCom Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an a
Monitoring Equipment
San Diego, CA
7,600 As of 2022
00000
000000000 00000

000000

rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute iru
0000000000 000000000
Germantown, MD
000 As of 0000
00000
000000000 00000

000000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000 000000000
San Diego, CA
0000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DexCom Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Senseonics Formerly VC-backed Germantown, MD 000 00000 000000000 00000
000000 00000000 00 Formerly VC-backed San Diego, CA 0000 00000 00000000000 00000
0000000 Venture Capital-Backed San Diego, CA 00 000.00 00000000000 000.00
00000000 00000000 Formerly PE-Backed Basel, Switzerland 0000 000000000000
00000000000 Formerly VC-backed New York, NY 000 00000 000000000 00000
You’re viewing 5 of 17 competitors. Get the full list »

DexCom Patents

  • 3,442

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 238

    Granted

  • 75

    Pending

  • 000

    Expiring in next 12 mo

DexCom Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230338654-A1 System and method for titrating basal insulin doses Pending 26-Apr-2022 0000000000
US-20230301553-A1 Continuous analyte monitoring sensor systems and methods of using the same Pending 18-Mar-2022 0000000000
US-20230293009-A1 Proximity pairing and security of a continuous analyte sensor system Pending 16-Mar-2022 000000000
US-20230263434-A1 Sensing systems and methods for providing decision support around kidney health and/or diabetes Pending 23-Feb-2022 00000000000
US-20230263439-A1 Systems and methods for multi-analyte sensing Pending 22-Feb-2022 A61B5/1495
To view DexCom’s complete patent history, request access »

DexCom Executive Team (50)

Name Title Board Seat Contact Info
Kevin Sayer Chief Executive Officer, Chairman of the Board of Directors & President
Jereme Sylvain Executive Vice President and Chief Financial Officer
Jake Leach Chief Operating Officer, Operations & Executive Vice President
Girish Naganathan Chief Technology Officer, Technology & Executive Vice President
Steven Pacelli JD Executive Vice President & Managing Director
You’re viewing 5 of 50 executive team members. Get the full list »

DexCom Board Members (15)

Name Representing Role Since
Barbara Kahn Self Board Member 000 0000
Bridgette Heller DexCom Board Member 000 0000
Eric Topol MD Self Board Member 000 0000
Karen Dahut DexCom Board Member 000 0000
Kevin Sayer DexCom Chief Executive Officer, Chairman of the Board of Directors & President 000 0000
You’re viewing 5 of 15 board members. Get the full list »

DexCom Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DexCom Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DexCom‘s full profile, request access.

Request a free trial

DexCom Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Epitel 31-Jan-2022 00000 0000 000.00 Monitoring Equipment 000000 00
New Zealand Medical & Scientific 29-Jul-2021 0000000000 Diagnostic Equipment
Beta Bionics 09-Jan-2019 00000 0000 0000 Monitoring Equipment
TypeZero 22-Aug-2018 0000000000 000.00 Other Healthcare Technology Systems 00000 000
Nintamed 02-May-2016 Merger/Acquisition 00.00 Monitoring Equipment 00000 000
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

DexCom Subsidiaries (2)

Company Name Industry Location Founded
Dexcom Ventures Corporate Venture Capital San Diego, CA 2021
New Zealand Medical & Scientific Diagnostic Equipment Auckland, New Zealand 0000
To view DexCom’s complete subsidiaries history, request access »

DexCom ESG

Risk Overview

Risk Rating

Updated October, 07, 2023

23.17 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Healthcare

Industry

00 of 626

Rank

00.00

Percentile

Medical Devices

Subindustry

00 of 213

Rank

0.00

Percentile

To view DexCom’s complete esg history, request access »